このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Strides Pharma Science 将来の成長

Future 基準チェック /46

Strides Pharma Science利益と収益がそれぞれ年間85.3%と11.2%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に16.2% 92.8%なると予測されています。

主要情報

85.3%

収益成長率

92.8%

EPS成長率

Pharmaceuticals 収益成長	17.1%
収益成長率	11.2%
将来の株主資本利益率	16.2%
アナリストカバレッジ	Low
最終更新日	23 May 2024

今後の成長に関する最新情報

Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 02

Recent updates

Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)

Apr 04

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Feb 29

Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story

Dec 23

We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt

Sep 26

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Jun 08

Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 02

Is Strides Pharma Science (NSE:STAR) A Risky Investment?

Jun 25

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Dec 21

Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50

Jul 28

Estimating The Fair Value Of Strides Pharma Science Limited (NSE:STAR)

Apr 13

Should Strides Pharma Science Limited (NSE:STAR) Be Part Of Your Dividend Portfolio?

Mar 04

These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively

Feb 15

Can Mixed Fundamentals Have A Negative Impact on Strides Pharma Science Limited (NSE:STAR) Current Share Price Momentum?

Jan 26

The Strides Pharma Science (NSE:STAR) Share Price Is Up 140% And Shareholders Are Boasting About It

Jan 11

Who Has Been Selling Strides Pharma Science Limited (NSE:STAR) Shares?

Dec 28

Are Strides Pharma Science's (NSE:STAR) Statutory Earnings A Good Guide To Its Underlying Profitability?

Dec 10

Could The Strides Pharma Science Limited (NSE:STAR) Ownership Structure Tell Us Something Useful?

Nov 25

業績と収益の成長予測

NSEI:STAR - アナリストの将来予測と過去の財務データ ( )INR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
3/31/2026	50,750	4,447	8,397	7,681	4
3/31/2025	46,169	4,327	6,839	6,839	3
3/31/2024	40,511	-1,248	5,829	7,011	N/A
12/31/2023	39,535	-1,525	N/A	N/A	N/A
9/30/2023	37,806	-2,280	3,043	3,903	N/A
6/30/2023	36,783	-924	N/A	N/A	N/A
3/31/2023	36,884	-2,212	-505	444	N/A
12/31/2022	35,680	-1,824	N/A	N/A	N/A
9/30/2022	34,976	-2,241	-2,101	-1,144	N/A
6/30/2022	33,220	-3,909	N/A	N/A	N/A
3/31/2022	30,703	-4,602	-4,012	-2,578	N/A
12/31/2021	31,127	-4,425	N/A	N/A	N/A
9/30/2021	31,504	-2,830	-1,188	1,572	N/A
6/30/2021	32,224	-543	N/A	N/A	N/A
3/31/2021	33,159	2,545	1,840	4,814	N/A
12/31/2020	30,260	28	N/A	N/A	N/A
9/30/2020	29,264	589	970	2,699	N/A
6/30/2020	28,480	1,266	N/A	N/A	N/A
3/31/2020	27,520	492	548	2,048	N/A
12/31/2019	35,828	2,859	N/A	N/A	N/A
9/30/2019	34,203	2,169	-1,519	1,896	N/A
6/30/2019	32,248	745	N/A	N/A	N/A
3/31/2019	21,784	840	-2,690	601	N/A
12/31/2018	28,547	-93	N/A	N/A	N/A
9/30/2018	28,090	139	N/A	N/A	N/A
6/30/2018	28,451	415	N/A	N/A	N/A
3/31/2018	28,451	544	-2,156	1,871	N/A
12/31/2017	35,810	1,050	N/A	N/A	N/A
9/30/2017	36,593	1,124	N/A	N/A	N/A
6/30/2017	35,357	1,712	N/A	N/A	N/A
3/31/2017	27,554	2,335	N/A	2,881	N/A
12/31/2016	37,237	2,840	N/A	N/A	N/A
9/30/2016	36,573	2,410	N/A	N/A	N/A
6/30/2016	34,189	2,168	N/A	N/A	N/A
3/31/2016	28,622	1,317	N/A	732	N/A
12/31/2015	24,901	1,152	N/A	N/A	N/A
9/30/2015	12,962	860	N/A	N/A	N/A
6/30/2015	12,105	244	N/A	N/A	N/A
3/31/2015	11,958	16	N/A	834	N/A
3/31/2014	10,728	-1,867	N/A	-2,173	N/A

アナリストによる今後の成長予測

収入対貯蓄率: STARは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 6.7% ) よりも高い成長率であると考えられます。

収益対市場: STAR今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: STAR今後 3 年以内に収益を上げることが予想されます。

収益対市場: STARの収益 ( 11.2% ) Indian市場 ( 9.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: STARの収益 ( 11.2% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: STARの自己資本利益率は、3年後には低くなると予測されています ( 16.2 %)。

Strides Pharma Science 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Price target increased by 20% to ₹994

Forecast breakeven date pushed back to 2025

Price target increased by 10% to ₹730

Price target increased by 10% to ₹530

Price target decreased by 7.2% to ₹462

Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Recent updates

Insufficient new directors

New minor risk - Dividend sustainability

Strides Pharma Science Limited Announces Chief Financial Officer Changes, Effective June 1, 2024

Price target increased by 20% to ₹994

Forecast breakeven date pushed back to 2025

Strides Pharma Science Limited to Report Q4, 2024 Results on May 22, 2024

Strides Pharma Science Limited Approves Appointment of Ameet P Hariani as Independent Director

Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Price target increased by 10% to ₹730

Third quarter 2024 earnings released: ₹0.49 loss per share (vs ₹8.86 loss in 3Q 2023)

Strides Pharma Science Limited to Report Q3, 2024 Results on Jan 30, 2024

Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story

Strides Pharma Global Pte. Limited Receives USFDA Approval for Generic Suprep®? Bowel Prep Kit

Now 21% undervalued

Strides Pharma Science Limited Announces Change in Management

Second quarter 2024 earnings released: ₹14.54 loss per share (vs ₹0.47 profit in 2Q 2023)

Strides Pharma Science Limited to Report Q2, 2024 Results on Oct 30, 2023

New major risk - Revenue and earnings growth

We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt

Strides Pharma Global Pte. Limited Receives Tentative United States Food & Drug Administration Approval for Dolutegravir Tablets

Strides Pharma Science Limited Announces Resignation of Ankit Gupta as Vice President and Head of Corporate Development and Strategy

Price target increased by 10% to ₹530

Upcoming dividend of ₹1.50 per share at 0.3% yield

Strides Pharma Science Limited to Report Q1, 2024 Results on Aug 02, 2023

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Strides Pharma Science Limited Recommends Dividend for Financial Year Ended March 31, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Strides Pharma Science Limited to Report Q4, 2023 Results on May 25, 2023

Price target decreased by 7.2% to ₹462

Third quarter 2023 earnings released: ₹8.86 loss per share (vs ₹13.55 loss in 3Q 2022)

Strides Pharma Science Limited to Report Q3, 2023 Results on Jan 24, 2023

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹2.54 (vs ₹18.12 loss in 2Q 2022)

Insufficient new directors

Strides Pharma Science Limited Announces Resignation of Director

Strides Pharma Science Limited to Report Q2, 2023 Results on Nov 14, 2022

Strides Pharma Science Limited, Annual General Meeting, Sep 09, 2022

Strides Pharma Science Limited, Annual General Meeting, Sep 09, 2022

Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

First quarter 2023 earnings released: ₹15.13 loss per share (vs ₹22.88 loss in 1Q 2022)

Strides Pharma Science Limited to Report Q1, 2023 Results on Jul 29, 2022

Is Strides Pharma Science (NSE:STAR) A Risky Investment?

Stelis Biopharma Limited and Strides Pharma Science Limited Receive the European Union Goods Manufacturing Practices (EU-GMP) Compliance Certificate

Now 20% undervalued after recent price drop

Strides Receives USFDA Approval for Ibuprofen Oral Suspension

Full year 2022 earnings: EPS misses analyst expectations

Strides Pharma Science Limited to Report Q4, 2022 Results on May 24, 2022

Price target decreased to ₹463

Insufficient new directors

Insufficient new directors

Strides Pharma Science Limited Announces Executive Changes

Founder & Non-Executive Chairman recently bought ₹50m worth of stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Strides Pharma Science Limited announced that it expects to receive INR 485 million in funding from Karuna Business Solutions LLP

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Price target decreased to ₹735

Second quarter 2022 earnings released: ₹18.12 loss per share (vs ₹7.38 profit in 2Q 2021)

Insider recently sold ₹1.5m worth of stock

Insider recently sold ₹14m worth of stock

First quarter 2022 earnings released: ₹22.88 loss per share (vs ₹11.56 profit in 1Q 2021)

Less than half of directors are independent

Upcoming dividend of ₹2.50 per share

Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50

Insider recently sold ₹2.8m worth of stock

Chief Human Resource Officer recently sold ₹4.1m worth of stock

TLC and Strides Pharma Science Limited Partner to Launch Liposomal Amphotericin B in India

Full year 2021 earnings released: EPS ₹28.40 (vs ₹5.49 in FY 2020)

Estimating The Fair Value Of Strides Pharma Science Limited (NSE:STAR)